Filing Details
Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS) filed a Form 8-K with the Securities and Exchange Commission on October 26, 2026, disclosing a material event.
8k filedNASDAQ:ABOS
Acumen Pharmaceuticals, Inc. (ABOS) Reports Material Event to SEC
Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS) filed a Form 8-K with the Securities and Exchange Commission on October 26, 2026, disclosing a material event.
At publication ·
What changed
Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS) · 8k filed
- Form
- 8-K
At a glance
Key takeaways
- Acumen Pharmaceuticals filed a Form 8-K on October 26, 2026 disclosing a material event to shareholders.
- The company's stock trades at $2.27 with a market capitalization of $190.2 million.
- Form 8-K filings report significant events such as leadership changes, material agreements, acquisitions, or asset sales.
Market Context
Acumen Pharmaceuticals, Inc.'s stock currently trades at $2.27 with a market capitalization of $190.2M. The Healthcare company's stock moved following the disclosure.
8-K filings report material events that shareholders should know about between regular quarterly or annual reports. These can include leadership changes, material agreements, acquisitions, asset sales, or changes to financial guidance. The specific nature of the event determines its significance for Acumen Pharmaceuticals, Inc.'s stock.
All SEC filings for Acumen Pharmaceuticals, Inc. are publicly available through the SEC's EDGAR database. Investors can set up alerts for new filings to stay current on material developments.
Related Tools: View ABOS Stock Page
Frequently Asked Questions
Where can I read ABOS's SEC filings?
Browse all filings on our ABOS SEC filings page.
What types of SEC filings does Acumen Pharmaceuticals, Inc. file?
Public companies like Acumen Pharmaceuticals, Inc. file annual reports (10-K), quarterly reports (10-Q), material events (8-K), and insider transactions (Form 4) with the SEC.